Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.”This is the second order from Well Lead outside the initial contract and further strengthens that end-customer sales in China are picking up. At the...
The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company. The partnership with one of the three largest orthopedic companies in the world confirms the strength of Bactiguard's technology in a global perspective and a new medical application for long-term...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday November 7, 2019 at 7:30 CET.In connection with this, a conference call for investors, analysts and media will be held at 11:00 CET on November 7. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report...
The members of the Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday 28 April 2020 at the company’s headoffice in Botkyrka, have now been appoined.The Nomination Committee for the 2020 Annual General Meeting in Bactiguard Holding AB (publ) will consist of the following members: Jan...
Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.”The order we have just received from Well Lead is the first outside of the initial contract and therefore an important milestone in our cooperation,...
Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization. “Our...
The product approval for Bactiguard's central venous catheters has been announced by the Mexican Ministry of Health. This provides new opportunities for Bactiguard in providing effective infection prevention for the most vulnerable patients in the second biggest market in Latin America.“We are finally through the registration...
Bactiguard’s indwelling urinary catheters (Foleys) are now approved for reimbursement in the Netherlands, which means that healthcare providers in the home care market can provide patients with Bactiguard's products for infection prevention and improve their quality of life. To be able to sell medical devices to the Dutch home care providers...
Stefan Grass with extensive clinical experience as a physician and researcher, combined with senior positions in the pharmaceutical industry, has been recruited to a newly established, global role as Chief Medical and Technology Officer. He will assume his position in October 2019 and report to the CEO.“As a physician and researcher...
The second quarter of 2019 was eventful. We increased our market coverage, secured funding for a very interesting research and development project, broadened the clinical evidence and strengthened executive management. Revenues and earnings were weaker than last year, but one must bear in mind that the second quarter 2018 was very strong.Second...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday August 8, 2019 at 8:00 CET.In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 8. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report...
A recently published clinical case study conducted at the Central Hospital in Karlstad, Sweden, shows that long-term use of Bactiguard coated Foley (BIP Foley) catheters reduces catheter associated urinary tract infections (CAUTIs) and greatly improves the patient’s quality of life. ”Permanent use of Foley catheters is often associated with...
The Board of Directors has appointed Chief Financial Officer (CFO) Cecilia Edström deputy CEO of Bactiguard, in addition to her current responsibilities.”Cecilia Edström was recruited to Bactiguard ahead of the IPO in 2014 and has had several roles in the company since then. This means that she has acquired a broad and deep...
Bactiguard has partnered with HANSAmed Limited (HANSAmed) to enter the Canadian market. The process to obtain regulatory (MDSAP) approval and Canadian product registration for the BIP portfolio will be financed by HANSAmed and is expected to be completed within 2 years.Canada has a population of 37 million people and the health care system has...
Bactiguard has entered a new partnership with Euromed Swiss AG (Euromed), a leading, specialized Swiss distributor of medical devices. Euromed will be distributing the entire Bactiguard product portfolio for infection prevention in Switzerland."By working with Euromed and their experienced, professional team, we will increase the pace of our...
In collaboration with researchers at Karolinska Institute, Bactiguard has been awarded a research grant of SEK 1.5 million for the development of noble metal-coated stents. The purpose of the project is to reduce the risk of thrombosis in connection with interventions in the bloodstream.“Stents save lives and are used in both acute care and...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 15 May, 2019 the following resolutions were made: The AGM adopted the income statements and balance sheets for 2018 and decided that no dividend for the financial year 2018 will be paid. Retained earnings and the company's loss for the year will be carried forward. The Board of...
A stable beginning of the yearThe beginning of 2019 was stable. Revenues increased somewhat, while the EBITDA result and margin greatly improved. 2018 was an exciting and eventful year for Bactiguard when we reached several important milestones, so we have high expectations for 2019.First quarter (January-March 2019) Revenues amounted to SEK 35.1...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Thursday May 9, 2019 at 8:00 CET.In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 9. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report and a...
Daniel Lund with many years’ experience in quality, production and supply chain management from the pharmaceutical industry, including AstraZeneca and Pfizer, has been recruited to a new role as Senior Vice President (SVP) Operations. At the same time, Jonas Östregård assumes responsibility for Marketing. Both Daniel and Jonas are...
The annual report for Bactiguard Holding AB (publ) 2018 is now available at www.bactiguard.comThe annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 15 and can be ordered by email to: info@bactiguard.se. This information is information that Bactiguard...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Wednesday, 15 May 2019 at 2:00 pm at the company´s headoffice at Alfred Nobels Allé 150 in Tullinge. Registration will commence at 1 pm. Right to participate and notice of...
The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes to the Annual General Meeting 2019, Professor Anna Martling and Thomas von Koch as new Board members.Anna Martling is Professor of Surgery and Dean of Campus North at Karolinska Institutet and at the same time Senior Consultant Surgeon in cancer at the Karolinska...
2018 was an exciting and eventful year for Bactiguard when we reached several important milestones, primarily strong growth in sales of our own product portfolio for infection prevention (BIP portfolio), the distribution and license agreement with Well Lead for China and the CE mark for orthopaedic trauma implants, which opens possibilities in a...
Bactiguard focuses operations in the Middle East and transfers its distribution to Iraq to a European distributor that, at the same time, takes over accounts receivable at a book value of SEK 17.1 million. The proceeds amount to SEK 12.8 million and, therefore, a write-down of accounts receivable corresponding to the balance of SEK 4.3 million is...
Bactiguard Holding AB (publ) publishes the year end report for 2018 on Thursday, February 7, 2019 at 8:00 CET.In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 7. CEO Christian Kinch and CFO Cecilia Edström will present the year end report and answer questions. The year...
